# Efficacy and Safety of Lobeglitazone Versus Sitagliptin

Study · id `cardio:ct-nct02480465` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02480465](<https://clinicaltrials.gov/study/NCT02480465>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02480465

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 248 participants.

## Technical summary

Registry record NCT02480465. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 248 participants (planned count; ClinicalTrials.gov record NCT02480465, source copy `cardio:ctgov-nct02480465-2015-07-08`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02480465, source copy `cardio:ctgov-nct02480465-2015-07-08`, retrieved 2026-10-26)
- Primary completion: 2016-12 (anticipated) (ClinicalTrials.gov record NCT02480465, source copy `cardio:ctgov-nct02480465-2015-07-08`, retrieved 2026-10-26)
- Completion: 2017-03 (anticipated) (ClinicalTrials.gov record NCT02480465, source copy `cardio:ctgov-nct02480465-2015-07-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02480465, source copy `cardio:ctgov-nct02480465-2015-07-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02480465-2015-07-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Lobeglitazone Versus Sitagliptin
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Lobelitazone 0.5mg
- Intervention (Drug): Sitagliptin 100mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: df773669b682eb132b264c33d03ad1095476f16607d32fce4ce0ef2af570c2f8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
